Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 10/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031261 | 0.90 | TP53 (0.40) | HSD17B10TP53KDM4EAKR1B10PTGDR2 | |
| SCHEMBL7398979 | 0.73 | ALDH1A1 (0.41) | TP53KDM4EAKR1B10PTGDR2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3586206 | 0.71 | KDM4E (0.37) | KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3586461 | 0.70 | LMNA (0.37) | HSD17B10HPGDKDM4EPTGDR2ALDH1A1 | |
| SCHEMBL14496036 | 0.68 | TP53 (0.42) | HSD17B10TP53KDM4EAKR1B10PTGDR2 | |
| SCHEMBL7134370 | 0.67 | F2 (0.41) | TPSAB1AKR1B10ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3583791 | 0.67 | KDM4E (0.39) | KDM4EPTGDR2ALDH1A1 | |
| SCHEMBL11504595 | 0.61 | ALDH1A1 (0.41) | KDM4EPTGDR2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1262416 | 0.61 | — | — | |
| SCHEMBL13498365 | 0.61 | ALDH1A1 (0.48) | HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | TPSAB1 607/4885HSD17B10 1901/4885CYP1A2 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.